1.07
전일 마감가:
$1.02
열려 있는:
$1.05
하루 거래량:
310.58K
Relative Volume:
1.05
시가총액:
$43.36M
수익:
$51.13M
순이익/손실:
$-93.80M
주가수익비율:
-0.4798
EPS:
-2.23
순현금흐름:
$-129.10M
1주 성능:
+5.94%
1개월 성능:
-9.32%
6개월 성능:
-68.99%
1년 성능:
-75.40%
Repare Therapeutics Inc Stock (RPTX) Company Profile
명칭
Repare Therapeutics Inc
전화
(857) 412-7018
주소
7171 FREDERICK BANTING, SAINT-LAURENT, QC
RPTX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RPTX
Repare Therapeutics Inc
|
1.07 | 43.36M | 51.13M | -93.80M | -129.10M | -2.23 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-06-09 | 업그레이드 | Stifel | Hold → Buy |
2023-02-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2023-01-06 | 개시 | CapitalOne | Overweight |
2022-04-12 | 다운그레이드 | Stifel | Buy → Hold |
2022-03-17 | 재개 | Goldman | Buy |
2021-09-23 | 개시 | Stifel | Buy |
2021-09-13 | 개시 | H.C. Wainwright | Buy |
2021-06-28 | 개시 | Guggenheim | Buy |
2021-03-01 | 개시 | Berenberg | Buy |
2020-10-28 | 개시 | Northland Capital | Outperform |
2020-07-14 | 개시 | Cowen | Outperform |
2020-07-14 | 개시 | Goldman | Neutral |
2020-07-14 | 개시 | Morgan Stanley | Overweight |
2020-07-14 | 개시 | Piper Sandler | Overweight |
모두보기
Repare Therapeutics Inc 주식(RPTX)의 최신 뉴스
Repare Therapeutics Appoints Steve Forte CEO - citybiz
Repare Therapeutics appoints CFO as new CEO - MSN
Repare Therapeutics Appoints Steve Forte as CEO to Succeed Lloyd Segal - MarketScreener
Repare Therapeutics Announces Leadership Changes in 2025 - TipRanks
Repare Therapeutics Names Forte as President, CEO - MarketWatch
Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds - TipRanks
Repare's New CEO Takes Helm With 3 Clinical Trial Readouts Coming in 2025 - Stock Titan
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Cathie Wood’s ARK trims Illumina, exits Repare Therapeutics stock - Investing.com
Repare Therapeutics stock hits 52-week low at $1.05 By Investing.com - Investing.com Australia
Repare Therapeutics stock hits 52-week low at $1.05 - Investing.com
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga
Fierce Biotech Layoff Tracker 2025: Cargo lays off 90% of staff; Empress halves workforce - Fierce Biotech
Repare therapeutics’ chief medical officer sells shares for $4,099 By Investing.com - Investing.com Australia
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta - Benzinga
Repare therapeutics’ chief scientific officer sells $6,396 in shares - Investing.com India
Repare therapeutics’ chief scientific officer sells $6,396 in shares By Investing.com - Investing.com South Africa
Repare therapeutics CEO Segal Lloyd Mitchell sells $24,144 in shares By Investing.com - Investing.com South Africa
Repare therapeutics CEO Segal Lloyd Mitchell sells $24,144 in shares - Investing.com
Repare Therapeutics CEO Sells Shares to Cover Tax Obligations - TradingView
HC Wainwright Issues Pessimistic Forecast for Repare Therapeutics (NASDAQ:RPTX) Stock Price - MarketBeat
What Makes Repare Therapeutics (RPTX) a New Buy Stock - Yahoo Finance
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
Repare Therapeutics stock target cut to $5 at H.C. Wainwright - Investing.com India
Repare Therapeutics stock target cut to $5 at H.C. Wainwright By Investing.com - Investing.com Canada
Strategic Pipeline Focus and Financial Stability Support Buy Rating for Repare Therapeutics - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Repare Therapeutics (NASDAQ:RPTX) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
New Hires at Repare Get Stock Options as Share Price Shows 67% Drop - Stock Titan
Here's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation - Yahoo Finance
Repare Therapeutics Focuses on Clinical Trials Amid Restructuring - TipRanks
Repare Therapeutics Restructures and Focuses on Key Clinical Trials - MSN
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results - CRISPR Medicine News
Repare Therapeutics anticipates key trial results by late 2025 - Investing.com Canada
Repare Therapeutics Inc. SEC 10-K Report - TradingView
Repare Therapeutics Inc (RPTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):